INTRODUCTION {#omy130s1}
============

Primary chest wall tumours are uncommon \[[@omy130C1]\]. Chondrosarcomas are the most common tumours arising from the chest wall \[[@omy130C1]\]. This neoplasm is more common in men than woman and occurs more often during the third and fourth decade of life \[[@omy130C1]\]. Some of the histopathologic variants are conventional, clear cell, mesenchymal and dedifferentiated chondrosarcomas \[[@omy130C2]\].

These tumours tend to present as a slowly growing mass. In rare cases, a p53 gene mutation may induce tumour progression and loss of growth control. Chondrosarcomas are largely considered to be resistant to conventional chemotherapy and radiotherapy \[[@omy130C2]\]. For this reason, wide margin surgical excision remains the best available surgical approach \[[@omy130C3]\]. When chondrosarcomas involve the chest wall, surgical excision may result in chest wall defects that require reconstruction to obliterate dead space, restore chest wall rigidity, preserve respiratory mechanics, maintain pulmonary function, protect intrathoracic organs, provide soft tissue coverage and minimize deformity \[[@omy130C4], [@omy130C5]\].

CASE REPORT {#omy130s2}
===========

A 66-year-old male patient with medical history significant for Hypertension, Gout and GERD presented to his primary care physician with a slow-growing chest mass over a 10-year period, associated with chest pain during the latter 5 years. Home medications included lisinopril, allopurinol and ranitidine. Patient denied alcohol consumption, illegal drugs, Tb exposure and previous history of malignancy or tobacco. A needle biopsy and a subsequent minimally invasive incisional biopsy, performed at a local hospital, were nondiagnostic. A later biopsy, performed at a tertiary care hospital and evaluated by the University Hospital Pathology service reported a high-grade chondrosarcoma. The patient initially refused surgery which prompted initial treatment with a Doxorubicin and Cisplatin chemotherapy regimen. Chemotherapy was discontinued after 10 months due to an accelerated mass growth.

At that point, physical examination was remarkable for a round, firm, non-tender chest wall mass, confirmed by chest radiography (Figs [1](#omy130F1){ref-type="fig"} and [2](#omy130F2){ref-type="fig"}). A magnetic resonance imaging (MRI) revealed a large right chest wall mass originating posteriorly to the right pectoralis major muscle, infiltrating the right anterior rib cage and extending into the right anterior thoracic cavity and the superior mediastinum. The mass measured 17.0 cm on the AP diameter, 20.6 cm on the transverse measurement and 18.3 cm in the cranio caudal diameter. The mass was adjacent to the Superior Vena Cava, and the right anterolateral surface of the ascending thoracic Aorta (Fig. [3](#omy130F3){ref-type="fig"}). The mass itself had multiple septa, cystic and solid components. It was producing complete destruction and encasement of the right anterior chest wall including the anterior right ribs and the right surface of the sternum. The patient was then evaluated by the Cardiothoracic and Plastic Surgery services, which recommended and together performed a complete resection with chest wall reconstruction.

![Massive anterior chest wall mass that measured approximately 25 cm in length.](omy130f01){#omy130F1}

![Chest X-ray showing a large lobulated soft tissue mass overlying the right chest.](omy130f02){#omy130F2}

![Thoracic MRI axial T2 image demonstrates a large, infiltrative heterogeneous soft tissue mass centred in the right chest wall with associated cortical destruction of the rib/lateral border of the sternum and invasion into the anterior mediastinum.](omy130f03){#omy130F3}

The surgery entailed elevation of a lateral skin-muscle flap, elevation of a medial skin-fascia flap, and exposure of the mass, while being careful to maintain margins free of malignancy: a layer of normal muscle tissue along its anterior surface and margins of normal bone or cartilage at the chest wall (Fig. [4](#omy130F4){ref-type="fig"}). En-bloc excision of the mass, with pectoralis major tissue, the right pectoralis minor muscle and the anterior chest wall, from the right nipple line to the left margin of the sternum, was performed, with a final specimen measurement of 27 × 24 × 17 cm, and a weight of 4.5 Kg (Fig. [5](#omy130F5){ref-type="fig"}).

![Intraoperative chest wall images, showing mass exposed.](omy130f04){#omy130F4}

![Post-surgical mass specimen that weighted approximately 10 pounds.](omy130f05){#omy130F5}

The excision resulted in resection of five ribs (second to sixth), near total resection of the sternal body, and exposure of the mediastinum and right lung (Fig. [6](#omy130F6){ref-type="fig"}). The chest wall was reconstructed with a synthetic bony cement (methyl methacrylate) construct, sandwiched between two embedded layers of polypropylene mesh. The prosthesis was designed with a paper template of the chest wall defect, constructed on a back table with the methyl methacrylateand shaped during the cement hardening reaction. The cement construct was inset in the chest wall defect and the fringe of mesh beyond the cement edge was fixed to the bony margins of the defect with polypropylene sutures, and to the surrounding soft tissues with polyglactin sutures. Wound closure was completed by advancing, tailoring, and inserting the aforementioned flaps, over the reconstructed chest wall. The patient was extubated in the operating room, had an uneventful postoperative course, was discharged home on postoperative day 11, and recovered well from his surgery (Figs [7](#omy130F7){ref-type="fig"} and [8](#omy130F8){ref-type="fig"}). Subsequently a P53 mutation was identified in tumour. Pre- and post-surgery pulmonary function tests revealed a normal spirometry, lung volumes and no abnormality in diffusing capacity (Table [1](#omy130TB1){ref-type="table"}).

![Intraoperative chest wall images, showing anterior thoracic cage with several incised ribs.](omy130f06){#omy130F6}

![Post-surgical chest X-ray without thoracic mass.](omy130f07){#omy130F7}

![Post-surgical and reconstructive surgery.](omy130f08){#omy130F8}

Table 1:Patient pulmonary function test---pre- and post-surgery.Lung function testPre-surgeryPost-surgeryFEV12.77 L (97%)2.95 L (105%)FVC3.26 L (89%)3.27 L (90%)FEV1/FVC85%90%TLC5.67 L5.61 LDLCO19.4 ml/mmHg/min19.3 ml/mmHg/minRV/TLC42%41%

DISCUSSION {#omy130s3}
==========

Primary malignant tumours of the chest wall are very uncommon in clinical practice, accounting for 8% of all chest wall tumours \[[@omy130C6]\]. The annual incidence of chest wall chondrosarcomas is less than 0.5 per million \[[@omy130C7]\]. Our patient presented the most common manifestation; a palpable mass associated with chest pain, which occurs in approximately 80% and 60% of cases, respectively \[[@omy130C1], [@omy130C8]\]. Chondrosarcomas constitute a group of neoplasms typical for the production of cartilage matrix by the tumour cells \[[@omy130C9]\]. Conventional chondrosarcoma is the most common type, but several rare subtypes exists, such as Dedifferentiated chondrosarcoma, Mesenchymal chondrosarcoma and clear cell chondrosarcoma \[[@omy130C3]\]. Primary chondrosarcomas arise de novo and secondary chondrosarcomas emerge from pre-existing benign cartilaginous neoplasms \[[@omy130C9]\]. The natural history and prognosis of chondrosarcomas is extremely variable \[[@omy130C9]\]. There have been few long-term studies on the treatment outcomes for chondrosarcomas \[[@omy130C9]\].

Computed tomography and MRI are useful to characterize the tumour and its extension \[[@omy130C7]\]. Different techniques are available to obtain a tissue diagnosis, including minimally invasive incisional or needle biopsies, however, excisional biopsies are preferred \[[@omy130C1], [@omy130C6], [@omy130C9]\]. Management strategies are diverse and depend strongly on the pathological diagnosis and the extent of disease. For grade I chondrosarcomas with intact cortex and absence of soft tissue mass, intraregional procedure such as curettage with adjunctive ablation can be considered \[[@omy130C9]\]. However, if there are aggressive imaging features such as cortical breakthrough, soft tissue mass or the tumour is grade II or higher, wide surgical excision is required \[[@omy130C9]\]. Wide, en-bloc surgical excision remains the best available treatment for intermediate to high-grade chondrosarcomas \[[@omy130C3]\]. The 5-year survival rate after resection with adequate surgical margins (4 cm on each side) was 100% compared with 50% in patients with inadequate surgical margins \[[@omy130C1]\]. Inadequate margin of resection is associated with worse overall survival and a higher chance of having local recurrence \[[@omy130C1]\]. Our patient initially refused surgery and had a poor response to chemotherapy. It is generally believed that this is due to penetration through the extracellular matrix, low percentage of dividing cells, and poor vascularity, chondrosarcomas are relatively chemo-radiotherapy resistant with the exception of mesenchymal chondrosarcoma with a limited number of cases reporting adequate response \[[@omy130C3]\].

In conclusion, patients with chondrosarcomas generally have a good prognosis when optimally diagnosed and treated \[[@omy130C3]\]. Our case reports interesting and unique findings due to the large size of the chondrosarcoma. One of the largest encountered when compared to reported literature, and its unusual growth and tumour progression after initiation of chemotherapy, which was related and has been associated to the presence of a p53 gene mutation \[[@omy130C10]--[@omy130C12]\]. Complete resection with wide surgical margin excision remains the best available treatment \[[@omy130C1]\]. It is highly recommended that the patient be referred as soon as possible to a multidisciplinary care centre with an experienced team to improve patient outcomes \[[@omy130C7]\].
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